Measurements of tumor vascular leakiness using DCE in brain tumors: Clinical applications

NMR in Biomedicine

Volumn 26, Issue 8, 2013, Pages 1042-1049

  Jain, Rajan ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Blood brain barrier; Brain tumor; Computed tomography; Dynamic contrast enhanced T1 weighted MR imaging (DCE MRI); Therapy; Vascular endothelial growth factor; Vascular perfusion; Vascular permeability

Indexed keywords

BLOOD-BRAIN BARRIER; BRAIN TUMORS; MR IMAGING; THERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR PERFUSION; VASCULAR PERMEABILITY;

BLOOD; BRAIN; COMPUTERIZED TOMOGRAPHY; MAGNETIC RESONANCE IMAGING;

TUMORS;

CONTRAST MEDIUM;

ARTICLE; BLOOD BRAIN BARRIER; BLOOD VOLUME; BRAIN TUMOR; CANCER PROGNOSIS; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DYNAMIC CONTRAST ENHANCED NUCLEAR MAGNETIC RESONANCE IMAGING; EXTRAVASCULAR SPACE; GLIOMA; HISTOPATHOLOGY; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION NECROSIS; RECURRENT CANCER; SCINTIGRAPHY; SIGNAL NOISE RATIO; STANDARDIZATION; SYSTEMATIC ERROR; TISSUE LEVEL; TREATMENT RESPONSE; TUMOR VASCULAR LEAKINESS; TUMOR VOLUME;

BLOOD-BRAIN BARRIER; BRAIN TUMOR; COMPUTED TOMOGRAPHY; DYNAMIC CONTRAST-ENHANCED T1-WEIGHTED MR IMAGING (DCE-MRI); THERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR PERFUSION; VASCULAR PERMEABILITY;

ANGIOGENESIS INHIBITORS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CAPILLARY PERMEABILITY; CEREBROVASCULAR CIRCULATION; CONTRAST MEDIA; DISEASE PROGRESSION; FORECASTING; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MICROCIRCULATION; NEOPLASM GRADING; NEOVASCULARIZATION, PATHOLOGIC; NEUROIMAGING; PROGNOSIS; RADIATION INJURIES; RADIOTHERAPY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84880943264     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.2994     Document Type: Article

References (69)

1. Folkman J The role of angiogenesis in tumor growth. Semin. Cancer Biol. 1992; 3: 65-71.
2. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992; 59: 845-848.
3. Shweiki D, Neeman M, Itin A, Keshet E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc. Natl. Acad. Sci. USA 1995; 92: 768-772.
4. Jackson A Imaging microvascular structure with contrast enhanced MRI. Br. J. Radiol. 2003; 76: S159-173.
5. Phongkitkarun S, Kobayashi S, Kan Z, Lee TY, Charnsangavej C. Quantification of angiogenesis by functional computed tomography in Matrigel model in rats. Acad. Radiol. 2004; 11: 573-582.
6. Bhujwalla ZM, Artemov D, Natarajan K, Solaiyappan M, Kollars P, Kristjansen PE. Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470. Clin. Cancer Res. 2003; 9: 355-362.
7. Raatschen HJ, Simon GH, Fu Y, Sennino B, Shames DM, Wendland MF, McDonald DM, Brasch RC. Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats. Radiology 2008; 247: 391-399.
8. Provenzale JM, Mukundan S, Dewhirst M. The role of blood-brain barrier permeability in brain tumor imaging and therapeutics. Am. J. Roentgenol. 2005; 185: 763-767.
9. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J. Magn. Reson. Imaging 1997; 7: 91-101.
10. Sourbron SP, Buckley DL. Tracer kinetic modelling in MRI: estimating perfusion and capillary permeability. Phys. Med. Biol. 2012; 57: R1-R33.
11. Cha S, Johnson G, Wadghiri YZ, Jin O, Babb J, Zagzag D, Turnbull DH. Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology. Magn. Reson. Med. 2003; 49: 848-855.
12. Mills SJ, Soh C, O'Connor JP, Rose CJ, Buonaccorsi G, Cheung S, Zhao S, Parker GJ, Jackson A. Enhancing fraction in glioma and its relationship to the tumoral vascular microenvironment: a dynamic contrast-enhanced MR imaging study. Am. J. Neuroradiol. 2010; 31: 726-731.
13. Roberts HC, Roberts TP, Brasch RC, Dillon WP. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. Am. J. Neuroradiol. 2000; 21: 891-899.
14. Li X, Rooney WD, Springer CS Jr. A unified magnetic resonance imaging pharmacokinetic theory: intravascular and extracellular contrast reagents. Magn. Reson. Med. 2005; 54: 1351-1359.
15. Purdie TG, Henderson E, Lee TY. Functional CT imaging of angiogenesis in rabbit VX2 soft-tissue tumour. Phys. Med. Biol. 2001; 46: 3161-3175.
16. Lee TY, Purdie TG, Stewart E. CT imaging of angiogenesis. Q. J. Nucl. Med. 2003; 47: 171-187.
17. Jain R, Ellika SK, Scarpace, L, Schultz LR, Rock JP, Gutierrez J, Patel SC, Ewing J, Mikkelsen T. Quantitative estimation of permeability surface-area product in astroglial brain tumors using perfusion CT and correlation with histopathological grade. Am. J. Neuroradiol. 2008; 29: 694-700.
18. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusible tracer: standardized quantities and symbols. J. Magn. Reson. Imaging 1999; 10: 223-232.
19. Bagher-Ebadian H, Jain R, Nejad-Davarani S, Mikkelsen T, Lu M, Jiang Q, Scarpace L, Arbab AS, Narang J, Soltanian-Zadeh H, Paudyal R, Ewing JR. Model selection for DCE-T1 studies in glioblastoma. Magn. Reson. Med. 2011. DOI: 10.1002/mrm.23211
20. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn. Reson. Med. 1991; 17: 357-367.
21. Choyke PL. Contrast agents for imaging tumor angiogenesis: is bigger better? Radiology 2005; 235: 1-2.
22. de Lussanet QG, Langereis S, Beets-Tan RG, van Genderen MH, Griffioen AW, van Engelshoven JM, Backes WH. Dynamic contrast enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice. Radiology 2005; 235: 65-72.
23. Persigehl T, Bieker R, Matuszewski L, Wall A, Kessler T, Kooijman H, Meier N, Ebert W, Berdel WE, Heindel W, Mesters RM, Bremer C. Antiangiogenic tumor treatment: early noninvasive monitoring with USPIO-enhanced MR imaging in mice. Radiology 2007; 244: 449-456.
24. Varallyay CG, Muldoon LL, Gahramanov S, Wu YJ, Goodman JA, Li X, Pike MM, Neuwelt EA. Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. J. Cereb. Blood Flow Metab. 2009; 29: 853-860.
25. Leach MO, Morgan B, Tofts PS, Buckley DL, Huang W, Horsfield MA, Chenevert TL, Collins DJ, Jackson A, Lomas D, Whitcher B, Clarke L, Plummer R, Judson I, Jones R, Alonzi R, Brunner T, Koh DM, Murphy P, Waterton JC, Parker G, Graves MJ, Scheenen TW, Redpath TW, Orton M, Karczmar G, Huisman H, Barentsz J, Padhani A. On behalf of the Experimental Cancer Medicine Centres Imaging Network Steering Committee. Imaging vascular function for early stage clinical trials using dynamic contrast enhanced magnetic resonance imaging. Eur. Radiol. 2012; 22: 1451-1464.
26. 2 mapping of the brain in a clinically acceptable time with DESPOT1 and DESPOT2. Magn. Reson. Med. 2005; 53: 237-241.
27. Zelhof B, Lowry M, Rodrigues G, Kraus S, Turnbull L. Description of magnetic resonance imaging-derived enhancement variables in pathologically confirmed prostate cancer and normal peripheral zone regions. BJU Int. 2009; 104: 621-627.
28. Alonzi R, Padhani AR, Allen C. Dynamic contrast enhanced MRI in prostate cancer. Eur. J. Radiol. 2007; 63: 335-350.
29. Kuhl CK, Mielcareck P, Klaschik S, Leutner C, Wardelmann E, Gieseke J, Schild HH. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 1999; 211: 101-110.
30. Rieber A, Brambs HJ, Gabelmann A, Heilmann V, Kreienberg R, Kuhn T. Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur. Radiol. 2002; 12: 1711-1719.
31. Rouvière O, Raudrant A, Ecochard R, Colin-Pangaud C, Pasquiou C, Bouvier R, Marechal JM, Lyonnet D. Characterization of time-enhancement curves of benign and malignant prostate tissue at dynamic MR imaging. Eur. Radiol. 2003; 13: 931-942.
32. Mayr NA, Yuh WT, Magnotta VA, Ehrhardt JC, Wheeler JA, Sorosky JI, Davis CS, Wen BC, Martin DD, Pelsang RE, Buller RE, Oberley LW, Mellenberg DE, Hussey DH. Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: a new noninvasive predictive assay. Int. J. Radiat. Oncol. Biol. Phys. 1996; 36: 623-633.
33. Zahra MA, Tan LT, Priest AN, Graves MJ, Arends M, Crawford RA, Brenton JD, Loms DJ, Sala E. Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer. Int. J. Radiat. Oncol. Biol. Phys. 2009; 74: 766-773.
34. Akisik MF, Sandrasegaran K, Bu G, Lin C, Hutchins GD, Chiorean EG. Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy. Radiology 2010; 256: 441-449.
35. Yankeelov TE, Gore JC. Dynamic contrast enhanced magnetic resonance imaging in oncology: theory, data acquisition, analysis, and examples. Curr. Med. Imaging Rev. 2009; 3: 91-107.
36. 1-weighted MR perfusion. Neuro Oncol. 2011; 13: 1037-1046.
37. Daniel BL, Yen YF, Glover GH, Ikeda DM, Birdwell RL, Sawyer-Glover AM, Black JW, Plevritis SK, Jeffrey SS, Herfkens RJ. Breast disease: dynamic spiral MR imaging. Radiology 1998; 209: 499-509.
38. Mussurakis S, Gibbs P, Horsman A. Primary breast abnormalities: selective pixel sampling on dynamic gadolinium-enhanced MR images. Radiology 1998; 206: 465-473.
39. Lev MH, Vedolin L. Permeability versus cerebral blood volume measurement in brain tumor evaluation: comparative clinical value and advice to authors. Am. J. Neuroradiol. 2006; 27: 418-419.
40. Aronen HJ, Gazit IE, Louis DN, Buchbinder BR, Pardo FS, Weisskoff RM, Harsh GR, Cosgrove GR, Halpern EF, Hochberg FH. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994; 191: 41-51.
41. Law M, Oh S, Babb JS, Wang E, Inglese M, Zagzag D, Knopp EA, Johnson G. Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging - prediction of patient clinical response. Radiology 2006; 238; 658-667.
42. Law M, Young RJ, Babb JS, Peccerelli N, Chheang S, Gruber ML, Miller DC, Golfinus JG, Zagzag D, Johnson G. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008; 247: 490-498.
43. Johnson G, Wetzel SG, Cha S, Babb J, Tofts PS. Measuring blood volume and vascular transfer constant from dynamic T(2)*-weighted contrast-enhanced MRI. Magn. Reson. Med. 2004; 51: 961-968.
44. Cao Y, Nagesh V, Hamstra D, Tsien CI, Ross BD, Chenevert TL, Junck L, Lawrence TS. The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas. Cancer Res. 2006; 66: 8912-8917.
45. Mills SJ, Patankar TA, Haroon HA, Baleriaux D, Swindell R, Jackson A. Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? Am. J. Neuroradiol. 2006; 27: 853-858.
46. Dhermain F, Saliou G, Parker F, Page P, Hoang-Xuan K, Lacroix C, Tournay E, Bourhis J, Duereux D. Microvascular leakage and contrast enhancement as prognostic factors for recurrence in unfavorable low-grade gliomas. J. Neurooncol 2010; 97(1): 81-88.
47. Jain R, Narang J, Griffith B, Bagher-Ebadian H, Scarpace L, Littenberg B, Mikkelsen T, Schultz L. Prognostic vascular imaging biomarkers in high-grade gliomas: tumor permeability as an adjunct to blood volume estimates. Acad. Radiol. 2013; 20(4): 478-485.
48. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Cassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van denBent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol. 2010; 28: 1963-1972.
49. Kong DS, Kim ST, Kim EH, Lim DH, Kim WS, Suh YL, Lee JI, Park K, Kim JH, Nam DH. Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status. Am. J. Neuroradiol. 2011; 32(2): 382-387.
50. Gahramanov S, Raslan AM, Muldoon LL, Hamilton BE, Rooney WD, Varallyay CG, Njus JM, Haluska M, Neuwalt EA. Potential for differentiation of pseudo-progression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. Int. J. Radiat. Oncol. Biol. Phys. 2011; 79: 514-523.
51. Tsien C, Galban CJ, Chenevert TL, Johnson TD, Hamstra DA, Sundgren PC, Junck L, Meyer CR, Rehemtulla A, Lawrence T, Ross BD. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J. Clin. Oncol. 2010; 28: 2293-2299.
52. Jain R, Narang J, Arbab SA, Schultz L, Scarpace L, Mikkelsen T, Babajani-Feremi A. Role of non-model-based semi-quantitative indices obtained from DCE T1 MR perfusion in differentiating pseudo-progression from true-progression. Neuro Oncol. 2011; 13: 140-140.
53. Hopewell JW, Wright EA. The nature of latent cerebral irradiation damage and its modification by hypertension. Br. J. Radiol. 1970; 43: 161-167.
54. Cha S, Lupo JM, Chen MH, Lamborn KR, McDermott MW, Berger MS, Nelson SJ, Dillon WP. Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Am. J. Neuroradiol. 2007; 28: 1078-1084.
55. Hu LS, Baxter LC, Smith KA, Feuerstein BG, Karis JP, Eschbacher JM, Coons SW, Nakaji P, Yeh RF, Debbins J, Heiserman JE. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from post treatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. Am. J. Neuroradiol. 2009; 30: 552-558.
56. Jain R, Scarpace L, Ellika S, Schultz LR, Rock JP, Rosenblum ML, Patel SC, Lee TY, Mikkelsen T. First-pass perfusion computed tomography: initial experience in differentiating recurrent brain tumors from radiation effects and radiation necrosis. Neurosurgery 2007; 61: 778-786.
57. Gaensler EH, Dillon WP, Edwards MS, Larson DA, Rosena W, Wilson CB. Radiation-induced telangiectasia in the brain simulates cryptic vascular malformations at MR imaging. Radiology 1994; 193: 629-636.
58. Barajas RF Jr, Chang JS, Segal MR, Parsa AT, McDermott MW, Berger MS, Cha S. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2009; 253: 486-496.
59. Barajas RF, Chang JS, Sneed PK, Segal MR, McDermott MW, Cha S. Distinguishing recurrent intra-axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Am. J. Neuroradiol. 2009; 30: 367-372.
60. Jain R, Narang J, Schultz L, Scarpace L, Saksena S, Brown S, Rock JP, Rosenblum M, Gutierrez J, Mikkelsen T. Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these add to other perfusion parameters in differentiating from recurrent/progressive tumors? Am. J. Neuroradiol. 2011; 32: 658-663.
61. Bisdas S, Naegele T, Ritz R, Dimostheni A, Pfannenberg C, Reimold M, Koh TS, Ernemann U. Distinguishing recurrent high-grade gliomas from radiation injury: a pilot study using dynamic contrast-enhanced MR imaging. Acad. Radiol. 2011; 18: 575-583.
62. Batchelor TT, Sorenson AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11(1): 83-95.
63. Sorenson AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 2009; 69: 5296-5300.
64. Cao Y, Tsien C, Shen Z, Tatro DS, Ten Haken R, Kessler ML, Chenevert TL, Lawrence TS. Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J. Clin. Oncol. 2005; 23: 4127-4136.
65. Thompson EM, Feenkel EP, Neuwelt EA. The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology 2011; 76; 87-93.
66. Yankeelov, TE, Rooney, WD, Li, X, Springer, CS Jr. Variation of the relaxographic " shutter-speed" for transcytolemmal water exchange affects the CR bolus-tracking curve shape. Magn. Reson. Med. 2003; 50(6): 1151-1169.
67. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson GC, Judson IR, Knopp MV, Maxwell RJ, McIntyre D, Padhani AR, Price P, Rathbone R, Rustin GJ, Tofts PS, Tozer GM, Vennart W, Waterton JC, Williams SR, Workman P. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br. J. Cancer 2005; 92(9): 1599-1610.
68. http://qibawiki.rsna.org/index.php?title=DCE-MRI_tech_ctte [21 January 2012].
69. Jain R, Poisson L, Narang J, Scarpace L, Rosenblum M, Rempel S, Mikkelsen T. Correlation of perfusion parameters with genes related to angiogenesis regulation in glioblastoma: a feasibility study. Am. J. Neuroradiol. 2012; 33(7): 1343-1348.